Johnson & Johnson (NYSE:JNJ) has increased its full-year sales outlook, even amid concerns about potential U.S. tariffs on pharmaceutical imports.
The company now projects annual revenue between $93.2 billion and $93.6 billion, up from the previous estimate of $91 billion to $91.8 billion.
Shares of Johnson & Johnson climbed over 1% in early U.S. trading on Wednesday.
President Donald Trump has indicated that his administration plans to introduce tariffs on pharmaceuticals by the end of July, starting with a “low tariff rate” designed to allow companies time to relocate manufacturing to the U.S. He also warned that a “very high tariff” would take effect within about a year.
Earlier in the year, Johnson & Johnson had estimated a $400 million impact from tariffs based on available information. However, following a recent U.S.-China trade truce framework, the company said the effect is “probably” closer to $200 million.
CFO Joseph Wolk noted that it is still premature to predict how tariffs will influence the company’s 2026 results, Reuters reported.
Despite these challenges, Johnson & Johnson posted adjusted second-quarter earnings per share of $2.77, surpassing analysts’ forecasts of $2.68, according to LSEG data cited by Reuters.
Revenue grew 5.8% year-over-year to $23.74 billion, exceeding the anticipated $22.84 billion. Strong demand was partly driven by the company’s Darzalex blood cancer treatment, which generated $3.54 billion in sales—above projections.
“Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways,” said CEO Joaquin Duato in a statement.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.